ID   LB996-RCC
AC   CVCL_1371
SY   LB996RCC; LB996; LOBE
DR   CLO; CLO_0009981
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1371
DR   Cell_Model_Passport; SIDM00180
DR   ChEMBL-Cells; CHEMBL3308309
DR   ChEMBL-Targets; CHEMBL2366110
DR   Cosmic; 753585
DR   Cosmic-CLP; 753585
DR   DepMap; ACH-002155
DR   EGA; EGAS00001000978
DR   GDSC; 753585
DR   GEO; GSM1670040
DR   IARC_TP53; 21468
DR   LINCS_LDP; LCL-1767
DR   PharmacoDB; LB996RCC_827_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1371
DR   Wikidata; Q54902108
RX   PubMed=10074909;
RX   PubMed=14762065;
RX   PubMed=15585611;
RX   PubMed=18698046;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=1.05%; East Asian, North=0%; East Asian, South=0.4%; South Asian=2.91%; European, North=45.92%; European, South=49.72% (PubMed=30894373).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,11
ST   D16S539: 11,12
ST   D5S818: 12
ST   D7S820: 10,11
ST   TH01: 9,10
ST   TPOX: 9,11
ST   vWA: 14,17
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_E912 ! LB996-EBV
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   PubMed=10074909; DOI=10.1002/(SICI)1097-0215(19990315)80:6<799::AID-IJC1>3.0.CO;2-U;
RA   Dumas F., Gala J.-L., Berteau P., Brasseur F., Eschwege P., Paradis V.,
RA   Lacour B., Philippe M., Loric S.;
RT   "Molecular expression of PSMA mRNA and protein in primary renal
RT   tumors.";
RL   Int. J. Cancer 80:799-803(1999).
//
RX   PubMed=14762065; DOI=10.1101/gr.2012304;
RA   Bignell G.R., Huang J., Greshock J., Watt S., Butler A.P., West S.,
RA   Grigorova M., Jones K.W., Wei W., Stratton M.R., Futreal P.A.,
RA   Weber B., Shapero M.H., Wooster R.;
RT   "High-resolution analysis of DNA copy number using oligonucleotide
RT   microarrays.";
RL   Genome Res. 14:287-295(2004).
//
RX   PubMed=15585611; DOI=10.1158/1078-0432.CCR-04-0072;
RA   Tykodi S.S., Warren E.H., Thompson J.A., Riddell S.R., Childs R.W.,
RA   Otterud B.E., Leppert M.F., Storb R., Sandmaier B.M.;
RT   "Allogeneic hematopoietic cell transplantation for metastatic renal
RT   cell carcinoma after nonmyeloablative conditioning: toxicity,
RT   clinical response, and immunological response to minor
RT   histocompatibility antigens.";
RL   Clin. Cancer Res. 10:7799-7811(2004).
//
RX   PubMed=18698046; DOI=10.1158/1078-0432.CCR-08-0028;
RA   Tykodi S.S., Fujii N., Vigneron N., Lu S.M., Mito J.K., Miranda M.X.,
RA   Chou J., Voong L.N., Thompson J.A., Sandmaier B.M., Cresswell P.,
RA   Van den Eynde B.J., Riddell S.R., Warren E.H.;
RT   "C19orf48 encodes a minor histocompatibility antigen recognized by
RT   CD8+ cytotoxic T cells from renal cell carcinoma patients.";
RL   Clin. Cancer Res. 14:5260-5269(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J.-D., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//